1. Home
  2. ABAT vs LXEO Comparison

ABAT vs LXEO Comparison

Compare ABAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Battery Technology Company

ABAT

American Battery Technology Company

N/A

Current Price

$2.69

Market Cap

341.0M

ML Signal

N/A

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

N/A

Current Price

$4.99

Market Cap

396.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ABAT
LXEO
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
341.0M
396.5M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
ABAT
LXEO
Price
$2.69
$4.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$6.00
$18.44
AVG Volume (30 Days)
3.2M
886.3K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
43.14
39.81
EPS
N/A
N/A
Revenue
N/A
$654,000.00
Revenue This Year
$145.40
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$3.99
52 Week High
$11.49
$10.99

Technical Indicators

Market Signals
Indicator
ABAT
LXEO
Relative Strength Index (RSI) 57.34 54.67
Support Level $2.51 $5.01
Resistance Level $2.73 $5.38
Average True Range (ATR) 0.15 0.28
MACD 0.04 0.02
Stochastic Oscillator 87.05 55.49

Price Performance

Historical Comparison
ABAT
LXEO

About ABAT American Battery Technology Company

American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: